Cargando…
Statin drugs enhance responses to immune checkpoint blockade in head and neck cancer models
BACKGROUND: Anti-PD-1 immune checkpoint blockade is approved for first-line treatment of recurrent/metastatic head and neck squamous cell carcinoma (HNSCC), but few patients respond. Statin drugs (HMG-CoA reductase inhibitors) are associated with superior survival in several cancer types, including...
Autores principales: | Kansal, Vikash, Burnham, Andre J, Kinney, Brendan L C, Saba, Nabil F, Paulos, Chrystal, Lesinski, Gregory B, Buchwald, Zachary S, Schmitt, Nicole C |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9853267/ https://www.ncbi.nlm.nih.gov/pubmed/36650022 http://dx.doi.org/10.1136/jitc-2022-005940 |
Ejemplares similares
-
Checkpoint blockade-induced CD8+ T cell differentiation in head and neck cancer responders
por: Zhou, Liye, et al.
Publicado: (2022) -
Combination of radiation therapy, bempegaldesleukin, and checkpoint blockade eradicates advanced solid tumors and metastases in mice
por: Pieper, Alexander A, et al.
Publicado: (2021) -
Modeling resistance of colorectal peritoneal metastases to immune checkpoint blockade in humanized mice
por: Küçükköse, Emre, et al.
Publicado: (2022) -
Targeting CD89 on tumor-associated macrophages overcomes resistance to immune checkpoint blockade
por: Xu, Lijun, et al.
Publicado: (2022) -
Dendritic cell therapy augments antitumor immunity triggered by CDK4/6 inhibition and immune checkpoint blockade by unleashing systemic CD4 T-cell responses
por: Kumar, Amrendra, et al.
Publicado: (2023)